Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Aug;52(6):656-659.
doi: 10.1016/j.arcmed.2021.03.004. Epub 2021 Mar 26.

Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis

Ahmad Amjed Toubasi  1 , Rand Bilal AbuAnzeh  1 , Bann Rami Khraisat  2 , Thuraya Nael Al-Sayegh  1 , Saif Aldeen AlRyalat  3
Affiliations
Meta-Analysis

Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis

Ahmad Amjed Toubasi et al. Arch Med Res. 2021 Aug.

Abstract

Background: The ongoing Coronavirus Infectious Disease (COVID-19) pandemic is a global health crisis that has had a magnanimous worldwide impact on all aspects of people's lives. Several observational studies investigated the relationship between Proton Pump Inhibitors use and the risk of COVID-19 development and mortality.

Aim of the study: The aim of this meta-analysis is to investigate the association between current PPIs use and the development of COVID-19 as well as its mortality.

Methods: Pubmed, Google Scholar, ScienceDirect and medRxiv were searched until November 21, 2020 using the following keywords: proton pump inhibitors and COVID-19 as well as their related MESH terms. The studies considered in the meta-analysis were either cohort or case-control in design and adjusted for confounding factors. The quality of the studies included in this meta-analysis was assessed using the Newcastle-Ottawa Scale. In addition, a random-effects model was used to calculate the pooled Odds Ratio (ORs) and the corresponding confidence interval (95% CI). Heterogeneity was evaluated using The Cochran's Q heterogeneity test and I2 statistic.

Results: Six observational studies with 195,230 participants were included. In this meta-analysis, current use of PPIs increased risk of COVID-19 development (OR = 1.19; 95% CI: 0.62-2.28) and mortality (OR = 1.67; 95% CI: 1.41-1.97).

Conclusions: Our meta-analysis indicates that current PPIs use significantly increased the risk of COVID-19 mortality, but it did not reach a significant threshold in regards to the risk of COVID-19 development.

Keywords: COVID-19; Gastroenterology; Global Health; Human; Pandemic; Proton Pump Inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA Flow Chart.
Figure 2
Figure 2
PPIs Use and the Risk COVID-19 Development.
Figure 3
Figure 3
PPIs Use and COVID-19 Mortality.
See this image and copyright information in PMC

References

    1. Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. JAMA. 2020;323:707–708. - PubMed
    1. WHO . World Health Organization; Geneva: 2020. WHO coronavirus disease (COVID-19) dashboard. Availabe online:Accessed November 18, 2020.
    1. Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020;92:401–402. - PMC - PubMed
    1. Nehra AK, Alexander JA, Loftus CG. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018;93:240–246. - PubMed
    1. Mao R, Qiu Y, He JS. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–678. - PMC - PubMed

Publication types

Substances